GlassScriptPhysician profile
Jeffrey M Reznik
NPI 1538292040
$931.69
in general payments reported to CMS, 2019-2025
16 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $65.27 · 2023: $369 · 2024: $229 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.37 | 2023-2025 | |
| Novo Nordisk INC | $137.22 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $121.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $89.27 | 2023-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $69.46 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.43 | 2024 | Xifaxan, Trulance |
| Abbott Laboratories | $40.26 | 2023-2024 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $33.26 | 2025 | Qelbree |
| Viiv Healthcare Company | $23.23 | 2023 | Apretude |
| Hologic Sales and Service, LLC | $21.92 | 2023 | Aptima |
| Astellas Pharma US INC | $21.51 | 2023 | Veozah |
| Dynavax Technologies Corporation | $21.08 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $19.76 | 2023 | Bexsero, Shingrix |
| Lilly USA, LLC | $17.42 | 2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $14.61 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Reznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.